Prostate Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Androgen Receptor & Microtubule Inhibitors, Gonadotropin Releasing Hormone (GnRH) Agonist, Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist), By Route of Administration (Oral & Parenteral), By Therapy (Chemo, Hormonal, Targeted, and Immuno Therapy), By Disease State (Metastatic Castration-Resistant Prostate Cancer & Non-Metastatic Castration-Resistant Prostate Cancer), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: December 15, 2025 | Format: PDF | Report ID: FBI112008

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
2. Pipeline Analysis, by Key Players
3. Overview of Alternative Therapies
4. Key Start-ups in the Market
5. New Product Launches, by Key Players
6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
7. Impact of COVID-19 on the Market
Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Germany
  2. U.K.
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Astellas Pharma Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Johnson & Johnson Services, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Ferring Pharmaceuticals Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. AbbVie Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Tolmar, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  10. Dendreon Pharmaceuticals LLC.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  11. Bayer AG
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
2. Pipeline Analysis, by Key Players
3. Overview of Alternative Therapies
4. Key Start-ups in the Market
5. New Product Launches, by Key Players
6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
7. Impact of COVID-19 on the Market
Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Germany
  2. U.K.
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Androgen Receptor Inhibitors
  2. Microtubule Inhibitors
  3. Gonadotropin Releasing Hormone (GnRH) Agonist
  4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  5. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
3. Market Analysis, Insights and Forecast – By Therapy
  1. Chemotherapy
  2. Hormonal Therapy
  3. Targeted therapy
  4. Immunotherapy
4. Market Analysis, Insights and Forecast – By Disease State
  1. Metastatic Castration-Resistant Prostate Cancer
  2. Non-Metastatic Castration-Resistant Prostate Cancer
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Astellas Pharma Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Johnson & Johnson Services, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Ferring Pharmaceuticals Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. AbbVie Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Tolmar, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  10. Dendreon Pharmaceuticals LLC.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  11. Bayer AG
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 1: Global Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 2: Global Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034

Figure 3: Global Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034

Figure 4: Global Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034

Figure 5: Global Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025 & 2034

Figure 6: Global Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 7: Global Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2025 & 2034

Figure 8: North America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 9: North America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 10: North America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 11: North America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 12: North America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 13: North America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 14: North America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034

Figure 15: North America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025

Figure 16: North America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 17: North America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 18: North America Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2025 & 2034

Figure 19: North America Prostate Cancer Therapeutics Market Value Share (%), By Country, 2025

Figure 20: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 21: Europe Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 22: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 23: Europe Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 24: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 25: Europe Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 26: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034

Figure 27: Europe Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025

Figure 28: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 29: Europe Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 30: Europe Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 31: Europe Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion),by Therapy, 2025 & 2034

Figure 37: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 38: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034

Figure 39: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025

Figure 40: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 41: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 42: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 43: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 44: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 45: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 46: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 47: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 48: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 49: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 50: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034

Figure 51: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025

Figure 52: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 53: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 54: Latin America Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 55: Latin America Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 56: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 57: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 58: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 59: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025

Figure 60: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034

Figure 61: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025

Figure 62: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034

Figure 63: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025

Figure 64: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 65: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 66: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 67: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 68: Global Prostate Cancer Therapeutics Market Share (%), By Company, 2025

List of Tables

Table 1: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 2: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 3: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021–2034

Table 4: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021–2034

Table 5: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 6: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 7: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 8: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 9: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021–2034

Table 10: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021–2034

Table 11: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 12: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034

Table 13: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 14: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 15: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021–2034

Table 16: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021–2034

Table 17: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 18: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 19: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 20: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 21: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021–2034

Table 22: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021–2034

Table 23: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 24: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 25: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 26: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 27: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021–2034

Table 28: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021–2034

Table 29: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 30: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 31: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 32: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 33: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021–2034

Table 34: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021–2034

Table 35: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 36: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 150

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com